---
title: "Zentalis Pharmaceuticals, Inc. (ZNTL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZNTL.US.md"
symbol: "ZNTL.US"
name: "Zentalis Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T13:53:16.447Z"
locales:
  - [en](https://longbridge.com/en/quote/ZNTL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZNTL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZNTL.US.md)
---

# Zentalis Pharmaceuticals, Inc. (ZNTL.US)

## Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [zentalis.com](https://zentalis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: D (0.72)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 17.35% |  |
| P/B Ratio | 1.76 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 380190245.76 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -49.18% | E |
| Profit Margin | -555.80% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -33.76% | E |
| Net Profit YoY | 16.72% | B |
| Total Assets YoY | -27.38% | E |
| Net Assets YoY | -28.63% | E |
| Cash Flow Margin | -17.99% | D |
| OCF YoY | -33.76% | E |
| Turnover | 0.07 | E |
| Gearing Ratio | 22.73% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zentalis Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "17.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.76",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "380190245.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-49.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-555.80%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-33.76%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "16.72%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-27.38%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-28.63%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-17.99%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-33.76%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.07",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "22.73%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.77 | 287/393 | - | - | - |
| PB | 1.76 | 155/393 | 0.63 | 0.40 | 0.33 |
| PS (TTM) | 6.44 | - | 5.95 | 3.99 | 3.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-10T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 44% |
| Hold | 5 | 56% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.23 |
| Highest Target | 10.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ZNTL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ZNTL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ZNTL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ZNTL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**